Monopar Therapeutics Inc. expected to post a loss of 62 cents a share - Earnings Preview

Monopar Therapeutics

07/08/2026 17:30

Monopar Therapeutics Inc. MNPR.OQ MNPR.O is expected to  show no change in quarterly revenue when it reports  results on August 10 (estimated) for the period ending June 30 2026

​LSEG's mean analyst estimate for Monopar Therapeutics Inc. is for a loss of 62 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Monopar Therapeutics Inc. is $117.00, about 2.7% below its last closing price of $120.21
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.80
-0.84
-0.46
Beat
44.9
Dec. 31 2026
-0.56
-0.49
-0.64
Missed
-29.8
Sep. 30 2025
-0.41
-0.43
-0.48
Missed
-11.6​
Jun. 30 2025
-0.46
-0.47
-0.35
Beat
25.8
​​Mar. 31 2025
-0.69
-0.68
-0.38
Beat
44.1
Dec. 31 2024
-0.42
-2.75
Missed
-554.8​
Sep. 30 2024
-0.48
-0.48
-0.37
Beat
22.4
Jun. 30 2024
-0.47
-0.47
-0.50
Missed
-7.1
This summary was machine generated August 7 at 16:30 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)